GPR35 and metabolic disease: We demonstrate that KA specifically prevents NLRP3 inflammasome activation by mitigating calcium mobilization and mitochondrial damage and mitochondrial ROS production via GPR35, which improves inflammatory diseases and metabolic disorders.